Amgen Inc. beat expectations on revenue and earnings, but issued lower guidance for the rest of the year, sending shares lower. The Thousand Oaks biotechnology company reported revenue of $6.5 billion, a 5.2 percent increase year-over-year that was driven by higher unit demand and partially offset by lower net selling prices. Amgen’s adjusted earnings increased 4 percent to $2.5 billion, or $4.38 per share, benefiting from increased revenues and fewer average shares outstanding because of a buyback program. Wall Street analysts expected $4.10 a share on average, according to Refinitiv. “As we look to the balance of the year, we are excited to be launching Lumakras, a first-in-class lung cancer treatment, and advancing a robust pipeline of potential new medicines to meet the demands of patients around the world,” Robert Bradway, Amgen’s chief executive, said in a statement.